



Universiteit
Leiden
The Netherlands

Pharmacotherapy and ventilatory control in health and disease

Simons, P.

Citation

Simons, P. (2024, June 5). *Pharmacotherapy and ventilatory control in health and disease*. Retrieved from <https://hdl.handle.net/1887/3762198>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3762198>

Note: To cite this publication please use the final published version (if applicable).

Pharmacotherapy
and
Ventilatory Control
in Health and Disease

Pieter Simons

The investigations described in chapters 2-5 of this thesis were performed in the Anesthesia & Pain Research Unit, Leiden University Medical Center, under the supervision of prof. dr. A. Dahan and dr. R. van der Schrier.

Copyright © 2024 *Pieter Simons*.

ISBN 978-94-6506-095-8

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior permission of the author.

Typeset by L^AT_EX

Cover design by Anneriek Simons

Printed by Ridderprint, the Netherlands

The printing of this thesis was financially supported by: ChipSoft and Trevena.

Pharmacotherapy and Ventilatory Control

in Health and Disease

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof. dr. ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op woensdag 5 juni 2024
klokke 11:15 uur

door

Pieter Simons
geboren te Enschede
in 1991

Promotiecomissie

Promotor: Prof. dr. A. Dahan

Copromotores: Dr. M. Niesters
Dr. M. van Velzen

Commissie: Prof. dr. E.Y. Sarton
Prof. dr. S. B. Karan (Rochester Medical Center)
Prof. dr. dr. M.W. Hollmann (Amsterdam UMC)
Prof. dr. H. Pijl
Prof. dr. J. Swen

The marriage of breath and beat is critical for life.

Ken D. O'Halloran - 2023

Contents

1	Introduction	1
2	<i>S</i> -ketamine oral thin film pharmacokinetics	13
3	<i>S</i> -ketamine oral thin film pharmacodynamics	41
4	Oliceridine respiratory effects	65
5	Diabetes, hyperinsulinemia, and the hypoxic ventilatory response	99
6	Summary, conclusions, and perspectives	121
7	Nederlandse samenvatting	131
	Addenda	135

List of Figures

2.1	<i>S</i> -ketamine PK - Plasma concentrations	22
2.2	<i>S</i> -ketamine PK - Final PK model	26
2.3	<i>S</i> -ketamine PK - Goodness of Fit (GOF) plots	30
2.4	<i>S</i> -ketamine PK - Simulations	31
2.5	<i>S</i> -ketamine PK - Simulations HNK	35
3.1	<i>S</i> -ketamine PD - Pharmacokinetic data	49
3.2	<i>S</i> -ketamine PD - Antinociceptive data	49
3.3	<i>S</i> -ketamine PD - Goodness-of-Fit plots	52
3.4	<i>S</i> -ketamine PD - Drug high data	53
3.5	<i>S</i> -ketamine PD - Visual Predictive Checks	54
3.6	<i>S</i> -ketamine PD - Steady-state concentration-effect relationships .	55
4.1	Oliceridine respiratory effects - \dot{V}_{E55} for four treatment arms . .	74
4.2	Oliceridine respiratory effects - Mean pharmacokinetic data . . .	76
4.3	Oliceridine respiratory effects - Goodness-of-Fit PK data	77
4.4	Oliceridine respiratory effects - Population PK model outcome .	78
4.5	Oliceridine respiratory effects - Population PD model outcome .	81
4.6	Oliceridine respiratory effects - Goodness-of-Fit PD data	82
4.7	Oliceridine respiratory effects - Simulation multiple dosing	85
4.8	Oliceridine respiratory effects - Queried adverse events	87
5.1	CB Hypoxia - Strobe diagram	105
5.2	CB Hypoxia - HVR	108
5.3	CB Hypoxia - Dejour	109
5.4	CB Hypoxia - Hemodynamics	111

List of Tables

2.1	<i>S</i> -ketamine PK - Subject characteristics	20
2.2	<i>S</i> -ketamine PK - Pharmacokinetic parameters OTF	23
2.3	<i>S</i> -ketamine PK - Adverse effects	24
2.4	<i>S</i> -ketamine PK - OTF pharmacokinetics	27
3.1	<i>S</i> -ketamine PD - Pharmacodynamic parameter estimates	51
4.1	Oliceridine respiratory effects - PK parameter estimates	79
4.2	Oliceridine respiratory effects - PD parameter estimates	83
4.3	Oliceridine respiratory effects - Adverse effects	86
5.1	CB Hypoxia - Subject characteristics	106